Timo Lappalainen, Orion CEO
With eyes on Keytruda patent cliff, Merck takes a $290M swing at prostate cancer
As the megablockbuster Keytruda is set to lose exclusivity in 2028, Merck has been furiously trying to shore up its pipeline prospects. A new deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
